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Background: Nanoparticles (NPs) play an important role in anticancer delivery systems. Surface modified NPs with
hydrophilic polymers such as human serum albumin (HSA) have long half-life in the blood circulation system.
Methods: The method of modified nanoprecipitation was utilized for encapsulation of paclitaxel (PTX) in poly
(lactic-co-glycolic acid) (PLGA). Para-maleimide benzoic hydrazide was conjugated to PLGA for the surface modifications
of PLGA NPs, and then HSA was attached on the surface of prepared NPs by maleimide attachment to thiol groups
(cysteines) of albumin. The application of HSA provides for the longer blood circulation of stealth NPs due to their
escape from reticuloendothelial system (RES). Then the physicochemical properties of NPs like surface
morphology, size, zeta potential, and in-vitro drug release were analyzed.
Results: The particle size of NPs ranged from 170 to 190 nm and increased about 20–30 nm after HSA conjugation.
The zeta potential was about -6 mV and it decreased further after HSA conjugation. The HSA conjugation in prepared
NPs was proved by Fourier transform infrared (FT-IR) spectroscopy, faster degradation of HSA in Differential scanning
calorimetry (DSC) characterization, and other evidences such as the increasing in size and the decreasing in zeta
potential. The PTX released in a biphasic mode for all colloidal suspensions. A sustained release profile for approximately
33 days was detected after a burst effect of the loaded drug. The in vitro cytotoxicity evaluation also indicated that the
HSA NPs are more cytotoxic than plain NPs.
Conclusions: HSA decoration of PLGA NPs may be a suitable method for longer blood circulation of NPs.
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Different scientists including pharmaceutics, chemists,
biologist, and nanotechnologist have been working
indefatigably to defeat cancer. A major interest in this
area is to improve drug targeting towards tumor cells
and decrease the unwilling effects of chemotherapeutics
[1-3]. Nanotechnology is very promising in this field and
increases the efficacy of targeting by introducing passive
and active targeting [4,5].* Correspondence: dinarvand@tums.ac.ir
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article, unless otherwise stated.The interest on utilizing NPs formulated from
biodegradable and biocompatible polymers such as the
most commonly used PLGA are rising rapidly [6].
These NPs are broadly studied as anticancer delivery
systems since it has special characteristics such as con-
trolled release and biocompatibility [6].
A new approach to evade the short half-life of the con-
ventional drug and allow targeted delivery to tumor cells
is drug targeting achieved by size engineering and sur-
face modification [7,8]. Vasculatures in tumor presents
several irregularities in contrast with normal vessels
resulting in enhanced permeation and retention (EPR)
effect [9,10] and this will cause the nanoparticles with
diameters less than 100 nm being selectively taken up byed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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distribution profile of the cytotoxic drugs change mas-
sively while they are incorporated with NPs, because
the modified particles are swiftly opsonised and mas-
sively cleared by mono nuclear phagocytes system (MPS)
[10-12]. Surface modification of particles with hydrophilic
polymers like polyethylene glycol (PEG) and albumin
leading to the development of long-circulating and stealth
particles for delivery of anticancer drugs [13,14]. Further-
more, the lack of lymph vessels and higher interstitial fluid
pressure in the most tumors than normal ones causes
inefficient removal of interstitial fluid and soluble macro-
molecules [15]. Therefore, the NPs mount up in the inter-
stitium which retards their uptake (EPR effect), unless
those particles are degraded [16,17].
The HSA coated NPs were prepared in two ways. First,
non-covalent interactions where HSA molecules only
saturate the surface without any covalent linkage [11] and
second, albumin conjugated particles were synthesised via
reaction between ξ-amino groups of lysine residues and
the protein ligand with aldehyde functional or carboxylic
acid [18,19]. The second method is more common.
Accordingly, we have developed a novel strategy that
benefit from high efficiency and selectivity of the thiol.
In this study we did a site-specific conjugation on the
HSA that in spite of the fact that it minimize a loss in
biological activity of it but meanwhile decrease im-
munogenicity. It happens because reagents that specif-
ically react with the thiol group of cysteines, and the
number of free cysteines on the surface of a protein is
much less [15]. HSA conjugation to surface of NPs was
done through the disulphide bonds between the HSA
and the paramaleimido benzoic hydrazid (PMBH) de-
rivative of PLGA. The encapsulation efficiency (EE),
drug release, and morphology of nanoparticles were
then investigated. At last cyto-toxicity of PTX loaded




PLGA (50:50, MW: 48000 g/mol) with carboxyl end group
and HSA were purchased from Sigma company. N, N’-
dicyclohexylcarbodiimide (DCC), N–hydroxysuccinimide
(NHS), and 3-(4,5-dimethyathiazol-2-yl)-2,5-diphenylte-
trazoliumbromide (MTT) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). PMBH, Na3PO4, NaH2PO4,
NaOH, sodium bicarbonate and also NaCl was obtained
from Merck. PTX purchased from Cipla Company.
Dulbecco’s modified eagle’s medium (DMEM), penicil-
lin, streptomycin antibiotic mixture and fetal bovine
serum (FBS) were obtained from Life technologies
(grand Island, NY, USA). Polyvinyl alcohol (PVA) was
acquired from Acros (Geel, Belgium). 2-(N-morpholinoethane sulfonic acid) (MES) was purchased from Fluka
(St. Louis, MO, USA). All other solvents and reagents
which are not stated were from Merck (Darmstadt,
Germany).
Methods
Synthesis of PLGA with functional group of maleimide
Maleimide-functionalized copolymer PLGA was synthe-
sized using the conjugation between paramaleimido ben-
zoic hydrazid (PMBH) and PLGA–COOH. PLGA–COOH
(5 g, 0.1 mmol) in 10 ml of methylene chloride was chan-
ged to PLGA–NHS with surfeit of N-hydroxysuccinimide
(NHS, 135 mg, 1.1 mmol) in the presence of N, N’-dicyclo-
hexylcarbodiimide (230 mg, 1.1 mmol). Then, 0.42 mol
PMBH was added to the solution of activated PLGA and
the reaction was allowed to proceed overnight on magnetic
stirrer. The mixture was evaporated using rotary evaporator
and the prepared film of PLGA-PMBH polymer was
washed properly using de-ionized water and dried nat-
urally for about two weeks. The synthesized polymer
was assessed using H-NMR and FT-IR spectroscopy.Preparation of PTX-loaded NPs
The method of modified nanoprecipitation was utilized
for the preparation of drug encapsulated into particles of
PLGA-PMBH [20-22]. In brief, 20 mg of polymer and
1.4 mg of PTX were dissolved in 4 ml of acetone and
then injected (rate = 0.5 ml/min) into 16 ml of aqueous
phase containing 0.5% PVA as surfactant and emulsified
by probe sonication (Misonix, USA) for 5 min with ampli-
tude of 10. Subsequently, the organic solution was evap-
orated gently on magnetic stirrer (600 rpm) for 9 hours.
The NPs were washed and recovered using centrifuge
process 25,000 rpm for 30 min (Sigma 3K30, Germany)
and then lyophilized at – 40°C for 48 h (Christ Alpha 1–4;
Germany). It should be mentioned that during the pro-
cedure, Several parameters in NPs preparation such as
surfactant concentration, ratio of organic to aqueous,
ratio of drug to polymer, and applied external energy
witch have critical effects on the eventual size of NPs
and drug loading were assessed in this experiment to
obtain optimize situation.
HSA conjugation on the surface of PLGA NPs
5 mg of NPs was dispersed in 4 ml of degassed deionized
water using bubbling nitrogen. HSA (10 mg/ml) were
dissolved in 5 ml of degassed deionized water which
have NaCl 0.15 M (pH 6.2–6.5) instantly before injecting
it into the suspension. 1 ml of degassed solution con-
tained ethylene diamine tetra acetic acid (EDTA) 4 mM
and NaCl 0.3 M (pH 6.2–6.5) then were added to the
suspension under the nitrogen pressure. The mixture
was put a side overnight for the conjugation to perform
Figure 1 FT-IR spectrum. (A) PLGA NPs (B) PLGA-HSA NPs.
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fied and the unreacted HSA was removed using centri-
fuge (18000 rpm, 30 min, 3 times).Measurement of size and zeta potential of NPs
Nearly 1 mg of NPs was suspended in 2 ml deionized
water using bath sonicator. Mean size and polydispersity
index (PDI) of NPs were evaluated using dynamic light
scattering (DLS) instrument (Nano ZS, Malvern Instru-
ments, UK). Afterward, samples were placed in an elec-
trophoretic cell and zeta potential was determined.Table 1 Particle size, zeta potential, encapsulation, and
loading of NPs before and after conjugation
NPs Size (nm) Zeta (mV) Encapsulation % Loading
PLGA 187.0 ± 10.0 -6.7 ± 1.5 80.1 ± 11.0 10.7 ± 2.6
PLGA-HSA 207.0 ± 5.2 -13.6 ± 1.4 75.4 ± 12.0 8.2 ± 1.3Surface morphology
Scanning electron microscopy (SEM, Philips XL 30,
Philips, The Netherlands) was used to determine the
shape and surface morphology of the produced NPs.
NPs were coated with gold under vacuum before scan-
ning electron microscopy.FT-IR analysis
To examine the conjugation was done correctly IR ana-
lysis. To perform this procedure we prepared a uniform
mixture of lyophilized PLGA and PLGA-HSA NPs (sep-
arately) and KBr.Differential scanning calorimetry (DSC)
Different ratio of physical mixture of raw materials included
PLGA, HSA, PTX and also PLGA NPs and PLGA-HSA
NPs were weighted equivalently (7 mg) and then sealed in
standard aluminum pans. The experiment carried out using
Figure 2 Nanoparticle size increase after HSA conjugation. 1 and 2 are PLGA NPs before HSA conjugation, and 3 and 4 are PLGA-HSA NPs after
HSA conjugation.
Figure 3 SEM micrographs of NPs with 30,000 times magnification.
(A) PLGA NPs (B) PLGA-HSA NPs.
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(10°C min/min) started from 40°C to 600°C.
Drug loading and encapsulation efficiency
To determine the drug loading and encapsulation
efficiency, PTX entrapped in the NPs was measured by
HPLC (Agilent LC1100, Agilent, Tokyo, Japan) at room
temperature. The column was C18 column (25 cm ×
0.46 cm internal diameter, pore size 5 μm; Teknokroma,
Barcelona, Spain). The mobile phase consisted of aceto-
nitrile/water (1/1 v/v). Lyophilized NPs (2.5 mg) were dis-
solved in acetonitrile (1 ml) (a common solvent for PLGA
and drug) and shaken lightly followed by sonication for
6 min. Then, 2 ml of methanol was added to precipitate
the polymer. The sample was filtered and drug quantity in
filterant was determined by HPLC analysis.




Encapsulation Efficiency % ¼ weight of drug in NPs
weight of feed NPs
 
100
In vitro drug release
In order to evaluate in vitro release profile of PTX from
PLGA and PLGA-HSA NPs, 2.5 mg of lyophilized samples
were dispersed in 5 ml phosphate buffer saline solution
(PBS, 0.01 M) containing 5% w/v of sodium dodecyl
sulphate (SDS) with different pH (5 and 7.4) [21]. After-
ward, suspensions poured into dialysis bags (cut off molecu-
lar weight 12000 g/mol) and immersed into the 50 ml of
PBS with similar pH to the PBS in the bags. Subsequently,
beakers placed on a shaker pre-set its temperature on 37°C
Esfandyari-Manesh et al. DARU Journal of Pharmaceutical Sciences  (2015) 23:28 Page 5 of 8and 100 cycles per minute for during 33 days because of
slow degradation proses of PLGA. For further assess-
ments, all 50 ml of media (PBS) replaced with a same
amount of new PBS at predetermined time intervals.
The amount of released PTX was determined by HPLC
in wavelength of 228 nm.In vitro cell viability
MTT test was used to study the in vitro cytotoxicity of
the subsequent PTX formulations on cell line of T47D:
PTX loaded PLGA-HSA NPs, PTX loaded PLGA NPs,
free PTX, and unloaded NPs.
T47D cells were seeded at the density of 1 × 104 viable
cells/well in 96-well plates (Costar, Chicago, IL) and it is
also incubated for 24 hours to providing enough time
for cell attachments. Then the formulation (100 μL, 1–200
nM, and 48 h) was used to substitute the medium. A stock
solution made in dimethyl sulfoxide (1 mg/ml PTX) for
PTX. The concentration of dimethyl sulfoxide kept under
0.5% since at this concentration it has no effect on prolifer-
ation of cells and RPMI-1640 culture medium was used as
diluents for preparing the working solution of free PTX
drug and NPs. 20 μl MTT (5 mg/ml in phosphate-buffered
saline) was added at specified periods of time to each well,
and after 3 – 4 hours the culture medium containing MTT
solution was eliminated. Then, micro plate reader (570 nm)Figure 4 DSC thermograms of PTX, HSA, PLGA NPs, and PLGA-HSA NPs.used to read it after dissolve of formazan crystals in di-
methyl sulfoxide (100 μL). At last following equation
used to evaluate cell viability:
Cell viability %ð Þ ¼ Ints=Intcontrolð Þ  100
In this equation Ints equal to the colorimetric intensity
of cells which is incubated with the samples, and Intcon-
trol is the colorimetric intensity of cells that incubated
with the phosphate-buffered saline only as positive control.
Results and discussion
Synthesis of polymer
PLGA functionalized with maleimide group was synthe-
sized and characterized. 1H-NMR and FT-IR analysis was
used for confirmation of the primary chemical structure
of PMBH–PLGA.
There was overlapping doublets at 1.6 ppm which are
a confirmation for the methyl groups of the lactic acid.
The multiples peaks at 4.8 ppm and 5.2 ppm correspond
to the –CH2 of glycolic acid and -CH of lactic acid, re-
spectively. The high complexity of the peaks at 4.8 ppm
and 5.2 ppm resulting from different sequences of gly-
colic acid and lactic in the backbone of polymer. There
are also some detectable proton signals from maleimide
and phenyl groups. Peaks which were present the hydro-
gens of linker are very weak compered to peaks present
Figure 5 In vitro PTX release profile from PLGA NPs and PLGA-HSA
NPs. Data points represent mean ± SD (n = 3).
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PLGA. A triplet peak on 7.2- 7.4 can be interoperating
as benzoic hydrogens and a small peak found on 6.6 ppm
shows the maleimide’s hydrogens [22].
Conjugation of PLGA-PMBH was shown by FT-IR
assessment (Figure 1). Formation of amide bonds are
one of the most important reactions in synthesis of
PLGA-PMBH. FTIR spectrum of synthesised polymer
verified the amide group formation by some peaks,
more specifically; the weak bands at 1620 cm-1 were
assigned to amide bonds. These results verified the for-
mation of PLGA-PMBH was done successfully.
Nanoparticles characterization
In the current study the modified nanoprecipitation
method was chosen for NPs preparation. Several parame-
ters in NPs preparation such as surfactant concentration,
ratio of organic to aqueous, ratio of drug to polymer, and
applied external energy have crucial effects on the even-
tual size of NPs and drug loading, so all of these pa-
rameters effects were assessed and the optimized
formulations were used to prepare NPs to obtain opti-
mized size [23]. Zeta potential, drug loading, and size
of NPs were assessed using DLS and HPLC, respect-
ively (Table 1). The evaluation of NPs size by DLS in-
strument revealed that the mean particle size of NPs
was 190 ± 10 nm and when it was conjugated with
HSA it increased about 20–30 nm and reached the
mean size of 210 ± 10 nm. Theoretically if HSA with axial
ratio of 2.66 nm and hydrodynamic radius of 3.7 nm con-
jugates in high amount around the surface of NPs, it
should increase the size of each NPs roughly 19.7 nm
and DLS assessment shows the predicted growth in di-
mension of each NPs (Figure 2). This phenomenon is
clearly observed in SEM pictures that are shown in
Figure 3. SEM pictures evaluation shows that NPs have
spherical shape and mostly have monodispersed size dis-
tribution. The nanoparticle’s zeta potential assessed by
DLS display that PLGA NPs have negative charge (-6 mV)
and the zeta potential reaches to -13 mV after HSA conju-
gation in PLGA-HSA NPs. HSA is also is a negative pro-
tein and conjugation will reduce the NPs charge [24].
DSC thermograms of pure PTX, pure HSA, and PTX
loaded PLGA NPs and PTX loaded PLGA-HSA NPs
demonstrated in Figure 4. In the drug diagram an endo-
thermic peak observed around 220°C and the absence of
that in NPs calorimetric curves proposes the lack of
crystallinity after NPs preparation; this suggests that
during NPs formation polymer hinders crystallization
of PTX and the drug exist in the amorphous state.
Other verifications, the differences between PLGA NPs
and PLGA-HSA NPs peaks show the conjugation of
HSA because of the faster degradation of HSA in PLGA-
HSA NPs compared to PLGA NPs [25].HSA conjugation
The infrared spectra of PLGA NPs and PLGA-HSA NPs
were recorded by using the KBr pellet method (Figure 1).
A very sharp peak at 1650 cm-1 in PLGA-HSA NPs that
obviously point towards amide bonds existed in amino
acids in HSA proved the conjugation take place correctly.
FT-IR spectrum, faster degradation of HSA in DSC
characterization, increasing the size of NPs, and decreas-
ing the zeta potential are reasons which were proved the
conjugation of HSA to PLGA-PMBH.
Drug release profile
In vitro drug release was evaluated in PBS with 2 differ-
ent pH including 5.5 and 7.4 to assess how the different
pH may affect the release profile. Acidic pH was chosen
to simulate drug release behavior in the cancer cells. It
also was examined before and after conjugation of HSA.
In all NPs, 80% of loaded PTX released continuously in
a sustained manner during 33 days when assessed in pH
of 5.5 and about 70% drug released when experiment
was carried out in neutral medium. This phenomena
Figure 6 The in vitro cytotoxicity of free PTX, PTX loaded PLGA NPs, and PTX loaded PLGA-HSA NPs with different amount of PTX on T47D breast
cancer cells. Data points represent mean ± SD (n = 3).
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it comes out of it by diffusion. Figure 5 shows that the
drug release in acidic environment is faster than neutral
ones for all NPs. Hence, this carrier can release drug
faster in acidic surroundings of tumors. Acidic pH en-
hances hydrolization of ester linkage in PLGA and help
encapsulated drug to release in control and sustain
manner [24-27].
In vitro cytotoxicity
Figure 6 shows the in vitro cytotoxicity of free PTX,
PTX loaded PLGA NPs, and PTX loaded PLGA-HSA
NPs with different amount of PTX on breast cancer
cells (T47D). Figure 6 illustrate that the cytotoxicity of
PTX loaded PLGA-HSA NPs was significantly higher
than the free PTX and PTX loaded PLGA NPs. More-
over, PTX loaded PLGA NPs have significantly more
cytotoxic effect than free PTX. The percent viability of
free PTX, PTX loaded PLGA NPs, and PTX loaded
PLGA-HSA NPs were 64%, 54%, and 43% in 15 nM
concentration, respectively. The enhancement of anti-
tumor activity of PLGA-HSA NPs may be caused by
gp60 (albondin) receptor and caveolar transport which
both help these particles to increased transendothelial
cell transportation of HSA [23,24]. First, HSA mole-
cules bind to gp60 receptors and this binding activates
caveolin. After caveolin configuration, HSA and other
plasma constituents transfer transversely the endothelial
cell to the interstitial space. Improved intratumor delivery
of PTX may also other reason for the increased antitumor
activity of PLGA-HSA NPs. Activated gp60 receptors
which are specific for HSA help transportation of this
molecule into tumor tissues by bypassing blood vessel
wall barriers [25]. Unloaded NPs tested to evaluate the
effect of polymerization and conjugation on cell viabilityand statistical analysis proved that these parameters do
not affect cell viability.
Conclusions
Preparation of the PTX loaded PLGA NPs were done by
modified nanoprecipitation method. The hydrophobic
PLGA NPs were decorated by hydrophilic HSA as novel an-
ticancer delivery system. The PMBH was used as linker for
the conjugation of HSA on the surface of PLGA NPs. The
drug loading and encapsulation efficiency were 13% and
80%, respectively. Our results demonstrated that by using
PMBH as linker and this method of nanoprecipitation,
HSA conjugated NPs would be obtained with desired size,
morphological, and drug loading properties. The in vitro
cytotoxicity also showed that the HSA decorated NPs are
more cytotoxic when compared with plain NPs and free
anticancer agent, so these NPs can be used successfully in
drug delivery of anticancer agents.
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